


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (Use as many sheets as necessary)

## **Complete if Known**

Application Number	10/678,836
Filing Date	October 3, 2003
First Named Inventor	Manoussos Perros
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC10925B

## **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number-Kind Code <sup>2</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<i>SN</i>	AA	US 5,968,947	10/19/1999	Zeneca Limited	
<i>SN</i>	AB	US 6,586,430	07/01/2003	Pfizer, Inc.	

## **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
<i>SN</i>	AC	WO 91/11172	08/08/1991	The University of Kansas		
	AD	WO 94/02518	02/03/1994	The University of Kansas		
	AE	WO 98/55148	12/10/1998	Janssen Pharmaceutica N.V.		
	AF	EP 0630887	05/20/1994	Zeneca Limited		
	AG	WO 97/19060	05/29/1997	Zeneca Limited		
	AH	WO 97/24325	07/10/1997	Takeda Chemical Industries Ltd.		
	AI	WO 98/02151	01/22/1998	Leukosite, Inc.		
	AJ	WO 98/25617	06/18/1998	Merck & Co., Inc.		
	AK	WO 98/25604	06/18/1998	Merck & Co., Inc.		
	AL	WO 99/37617	06/18/1998	Merck & Co., Inc.		
	AM	EP 0903349	08/10/1998	F. Hoffmann-La Roche AG		
<i>SN</i>	AN	WO 99/04794	02/04/1999	Merck & Co., Inc.		

EXAMINER:

*E. Huang*

DATE CONSIDERED:


*1/28/05*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with each communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (Use as many sheets as necessary)

## **Compleat if Known**

Application Number	10/678,836
Filing Date	October 3, 2003
First Named Inventor	Manoussos Perros
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC10925B

2/18	AO	WO 99/17773	04/15/1999	Smithkline Beecham Corp.	
2/18	AP	WO 99/37619	07/29/1999	Leukosite, Inc.	
2/18	AQ	WO 00/38680	07/06/2000	Pfizer Limited	

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
2/18	AR	BERGE, et. al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Science</i> , 1977, 1-19, Vol 66., No. 1.	
	AS	CASCIERI, et. al., "The Chemokine/Chemokine Receptor Family: Potential and Progress for Therapeutic Intervention," <i>Current Opinion Chem. Biol.</i> 2000, 420-427, Vol. 4, No. 4.	
	AT	COMBADIÈRE, et. al., "Cloning and Functional Expression of CC CKR5, a Human Monocyte CC Chemokine Receptor Selective for MIP-1 $\alpha$ , MIP-1 $\beta$ , and RANTES," <i>Journal of Leukocyte Biology</i> , 1996, 147-152, Vol. 60.	
	AU	CONNOR, et. al., "VPR Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes," <i>Virology</i> , 1995, 935-944, Vol. 206, No. 2.	
	AV	DIMITROV, et. al., "Microculture Assay for Isolation of Human Immunodeficiency Virus Type 1 and for Titration of Infected Peripheral Blood Mononuclear Cells," <i>Journal of Clinical Microbiology</i> , 1990, 734-737, Vol 28, No. 4.	
2/18	AW	HESELGESSER, J., et. al., "Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor," <i>Journal of Biological Chemistry</i> , 1998, 15687-15692, Vol. 273, No. 25.	

Do not receive the following  
For Application  
AF-AQ

EXAMINER:

2/18 Huang

DATE CONSIDERED:

4/28/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.